The Manufacturers Life Insurance Company Increases Stake in Immunocore Holdings plc (NASDAQ:IMCR)

The Manufacturers Life Insurance Company grew its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 6.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 114,151 shares of the company’s stock after purchasing an additional 6,760 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.23% of Immunocore worth $3,367,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in IMCR. Principal Financial Group Inc. raised its position in Immunocore by 25.0% during the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock valued at $17,007,000 after purchasing an additional 109,206 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in Immunocore by 125.4% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock worth $1,463,000 after buying an additional 27,598 shares during the period. Crossmark Global Holdings Inc. grew its holdings in shares of Immunocore by 36.7% during the 4th quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company’s stock worth $1,121,000 after acquiring an additional 10,217 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after acquiring an additional 960 shares in the last quarter. Finally, Assetmark Inc. lifted its stake in shares of Immunocore by 5.3% in the 4th quarter. Assetmark Inc. now owns 32,171 shares of the company’s stock valued at $949,000 after purchasing an additional 1,616 shares during the period. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Down 4.7 %

IMCR stock opened at $28.40 on Friday. The stock has a market capitalization of $1.42 billion, a P/E ratio of -29.89 and a beta of 0.75. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore Holdings plc has a 1-year low of $23.15 and a 1-year high of $60.25. The business has a fifty day moving average price of $28.81 and a 200-day moving average price of $30.17.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.45. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business had revenue of $125.13 million for the quarter, compared to analysts’ expectations of $108.82 million. During the same quarter in the prior year, the business earned ($0.49) EPS. The business’s revenue for the quarter was up 33.6% compared to the same quarter last year. Equities analysts forecast that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IMCR has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and set a $71.00 price objective on shares of Immunocore in a research report on Thursday, April 10th. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research note on Wednesday, March 12th. Mizuho decreased their target price on shares of Immunocore from $38.00 to $33.00 and set a “neutral” rating for the company in a research note on Monday, April 7th. JPMorgan Chase & Co. dropped their price target on Immunocore from $54.00 to $50.00 and set an “overweight” rating on the stock in a research report on Monday, April 14th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.13.

Insider Buying and Selling

In other news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the business’s stock in a transaction on Monday, March 17th. The stock was acquired at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the purchase, the director now directly owns 2,144,060 shares in the company, valued at $63,721,463.20. This trade represents a 60.40 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.40% of the stock is currently owned by corporate insiders.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.